ImmunoGen, Inc.
IMGNN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
IMGN News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Mirvetuximab Soravtansine
Epithelial Ovarian Cancer
Paclitaxel
Epithelial Ovarian Cancer
IMGC936
Advanced Solid Tumor
BB-10901
Small Cell Lung Cancer
Carboplatin
Epithelial Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mirvetuximab Soravtansine | Phase 3 | Epithelial Ovarian Cancer | - | - |
Paclitaxel | Phase 3 | Epithelial Ovarian Cancer | - | - |
IMGC936 | Phase 2 | Advanced Solid Tumor | - | - |
BB-10901 | Phase 2 | Small Cell Lung Cancer | - | - |
Carboplatin | Phase 2 | Epithelial Ovarian Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply